A clinical-stage biotechnology company focused on developing therapies that target DNA repair mechanisms to treat cancer. Its research centers on small‑molecule drugs designed to exploit synthetic lethality in tumor cells, with candidates evaluated in early-stage clinical trials. Investors track the...
4 members of Congress have disclosed 8 trades in Cyteir Therapeutics, Inc. (CYT), a Healthcare company. The buy/sell breakdown shows 6 purchases versus 2 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2015-08-05 | JAMES B. RENACCI | sell | $1K – $15K |
| 2015-04-27 | Ed Whitfield | buy | $1K – $15K |
| 2012-12-04 | Nick J. Rahall | sell | $6,941.14 |
| 2012-10-04 | Nick J. Rahall | buy | $6,426.10 |
| 2011-07-09 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2011-03-05 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2011-02-03 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2010-10-12 | MICHAEL T. MCCAUL | buy | $1K – $15K |